SEC Form 4 · accession 0001209191-17-045272
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curt A. Herberts III
Officer — Sr.VP & Chief Business Officer
Period of report
Jul 14, 2017
Accepted (ET)
Jul 14, 2017 · 8:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 14, 2017 | M | 172 | $3.99 | A | 35,517 | D | |
| Common Stock | Jul 14, 2017 | S | 172 | $10.00 | D | 35,345 | D | |
| Common Stock | Jul 14, 2017 | S | 14,828 | $10.00 | D | 20,517 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.99 | Jul 14, 2017 | M | 172 | D | — | Oct 17, 2020 | Common Stock | 172 | 3,474 | D |
Explanation of responses
- F1All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
- F2The shares underlying the stock option are fully vested and exercisable.